ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $32.06 million versus the consensus estimate of $31.88 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Truist says US banks cautiously optimistic on deposit growth
• Fermi files statement opposing former CEO's shareholder meeting proposal